Prevalencia, manifestaciones clínicas y factores asociados al COVID-19 de larga duración: Prevalence, clinical manifestations, and associated factors of long COVID-19

Daniel Rojas-Bolivar; Fabiola Huaroto-Ramírez; Maricela  Curisinche-Rojas; Diana  Gonzales Zurita; Ericson Gutiérrez

doi:10.25176/RFMH.v22i3.5009

Authors

Daniel Rojas-Bolivar Unidad de Análisis y Generación de Evidencias en Salud Pública, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú. https://orcid.org/0000-0003-0585-4155
Fabiola Huaroto-Ramírez Unidad de Análisis y Generación de Evidencias en Salud Pública, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú. https://orcid.org/0000-0002-7323-230X
Maricela Curisinche-Rojas Unidad de Análisis y Generación de Evidencias en Salud Pública, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú. https://orcid.org/0000-0003-4015-6627
Diana Gonzales Zurita Unidad de Análisis y Generación de Evidencias en Salud Pública, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú. https://orcid.org/0000-0002-8917-0262
Ericson Gutiérrez Instituto de Investigación en Ciencias Biomédicas (INICIB), Universidad Ricardo Palma, Lima. Perú. https://orcid.org/0000-0003-4725-6284

DOI:

https://doi.org/10.25176/RFMH.v22i3.5009

Keywords:

COVID-19, post-acute COVID-19 syndrome, long-COVID

Abstract

The aim was to describe the prevalence, clinical manifestations, and associated factors of long-COVID. Bibliographic research of systematic reviews and meta-analyses was carried out in MEDLINE (through PubMed) until April 7th, 2022. 37 articles were found and 3 were included. Evidence quality was assessed via AMSTAR 2 criteria. Long-COVID prevalence is 43% (IC95%: 39% – 46%). Main clinical manifestations were weakness (41% [IC95%: 25% – 59%]), malaise (33% [IC95%: 15% – 57%]), fatigue (31% [IC95%: 24% – 39%]), concentration impairment (26% [IC95%: 21% – 32%]), and breathlessness (25% [IC95%: 18% – 34%]). Factors associated with long COVID were female sex, initial disease severity, age, and presence of comorbidities.